The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Disease Areas
Poster
Dato-DXd
ESMO Asia 2025 | December 5-7, 2025
Lung Cancer
A multicenter, real-world study of treatment patterns and clinical outcomes of later-line therapy in Chinese patients with advanced non-small cell lung cancer harboring non-actionable genomic alterations (RECAP Study)
Hanxiao Chen
View presentation
Poster
I-DXd
WCLC 2025 | September 6-9 2025
Lung Cancer
A phase 1b/2 study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer
Melissa Johnson
View presentation
Poster
I-DXd
ESMO 2025 | October 17-21, 2025
Lung Cancer
A phase 1b/2 study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer
Jair Bar
View presentation
Poster
I-DXd
WCLC 2026 | 12-15 September, 2026
Lung Cancer
A phase 1b/2, open-Label study evaluating gocatamig and ifinatamab deruxtecan for extensive-stage small-cell lung cancer
M. Gutierrez
View presentation
Poster
I-DXd
ISPOR 2026 | May 17-20, 2026
Lung Cancer
An indirect treatment comparison of ifinatamab deruxtecan (I-DXd) versus real-world physicians’ choice of therapy in patients previously treated with at least 2 lines of therapy for extensive-stage small cell lung cancer
Jie Meng
View presentation
Poster
Other/Multi
WCLC 2026 | 12-15 September, 2026
Lung Cancer
Clinical impact of NY-ESO expression on the efficacy of immune checkpoint inhibitors in lung squamous cell carcinoma
Motohiro Izumi
View presentation
Poster
Other/Multi
WCLC 2026 | 12-15 September, 2026
Lung Cancer
Clinical outcomes in patients with advanced large-cell neuroendocrine carcinoma of the lung: A systematic literature review and meta-analysis
C.M. Gay
View presentation
Poster
T-DXd
WCLC 2025 | September 6-9 2025
Lung Cancer
Concordance of HER2 overexpression by IHC and ERBB2 gene amplification by NGS in lung cancer
Samrat Yeramaneni
View presentation
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
Lung Cancer
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Toshihiko Doi
View presentation
Poster
Dato-DXd
ACoP16 | October 18-21, 2025
Lung Cancer
Exposure-response analysis of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in patients with advanced or metastatic non-small cell lung cancer
Jaydeep Sinha
View presentation
Pages: 1  2  3  4  
Connect with an MSL
Linkedin Icon Twitter Icon

©2026  Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24